'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
- PMID: 35896282
- PMCID: PMC9335059
- DOI: 10.1136/rmdopen-2022-002387
'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
Abstract
The European Alliance of Associations for Rheumatology recently defined difficult to treat (D2T) rheumatoid arthritis (RA) and provided points to consider in its management. This review summarises the key concepts of D2T-RA that underpinned this recent guidance. D2T-RA is primarily characterised by failure of at least two different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drug (DMARDs) with evidence of active/progressive disease. The basis for progressive disease, however, is not limited to clear inflammatory joint pathology, capturing wider contributors to treatment cycling such as comorbidity, obesity and fibromyalgia. This means D2T-RA comprises a heterogeneous population, with a proportion within this exhibiting bona fide treatment-refractory disease. The management points to consider, however, emphasise the importance of checking for the presence of inflammatory pathology before further treatment change. This review suggests additional considerations in the definition of D2T-RA, the potential value in identifying D2T traits and intervening before the development of D2T-RA state and the need for real world evidence of targeted synthetic DMARD in this population to compare to recent trial data. Finally, the review asks whether the presence of D2T-RA implies a failure to treat effectively from the outset, and the need for pharmacological and non-pharmacological management approaches to address the wider D2T-RA population effectively.
Keywords: biological therapy; rheumatoid arthritis; therapeutics.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MHB is supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre and is in receipt of an NIHR Senior Investigator award.
Figures





Similar articles
-
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.Curr Rheumatol Rep. 2023 Dec;25(12):285-294. doi: 10.1007/s11926-023-01117-6. Curr Rheumatol Rep. 2023. PMID: 37776482 Review.
-
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.Adv Rheumatol. 2024 Aug 6;64(1):55. doi: 10.1186/s42358-024-00396-6. Adv Rheumatol. 2024. PMID: 39107865
-
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.Arthritis Res Ther. 2023 Sep 19;25(1):174. doi: 10.1186/s13075-023-03165-w. Arthritis Res Ther. 2023. PMID: 37726808 Free PMC article.
-
Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry.Rheumatology (Oxford). 2025 Mar 1;64(3):1102-1110. doi: 10.1093/rheumatology/keae318. Rheumatology (Oxford). 2025. PMID: 38837701 Free PMC article.
-
Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?Rheumatology (Oxford). 2025 Jan 1;64(1):65-73. doi: 10.1093/rheumatology/keae544. Rheumatology (Oxford). 2025. PMID: 39383505 Free PMC article. Review.
Cited by
-
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender.Arthritis Res Ther. 2025 Jan 3;27(1):2. doi: 10.1186/s13075-024-03432-4. Arthritis Res Ther. 2025. PMID: 39754234 Free PMC article.
-
Management of Rheumatoid Arthritis in Primary Care: A Scoping Review.Int J Environ Res Public Health. 2024 May 22;21(6):662. doi: 10.3390/ijerph21060662. Int J Environ Res Public Health. 2024. PMID: 38928909 Free PMC article.
-
Effectiveness of ultrasound-guided intra-articular drug injections in treating sternoclavicular arthritis: a single-group observational study.Quant Imaging Med Surg. 2025 Jan 2;15(1):752-759. doi: 10.21037/qims-24-1657. Epub 2024 Dec 19. Quant Imaging Med Surg. 2025. PMID: 39839015 Free PMC article.
-
Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.J Clin Med. 2025 Apr 10;14(8):2605. doi: 10.3390/jcm14082605. J Clin Med. 2025. PMID: 40283434 Free PMC article. Review.
-
The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis.Front Pharmacol. 2024 May 31;15:1380098. doi: 10.3389/fphar.2024.1380098. eCollection 2024. Front Pharmacol. 2024. PMID: 38881875 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical